All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Novel Oncology Drugs in Clinical Development in GERMANY

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Immatics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Immatics Announces Business Combination with Arya Sciences Acquisition Corp

Contact the Supplier

Lead Product(s): T cell immunotherapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Arya Sciences Acquisition Corp

Deal Size: $252.0 million Upfront Cash: Undisclosed

Deal Type: Agreement March 17, 2020

Details:

Deal aims at identifying cancer targets and developing the right TCRs for immunotherapies.

ProBioGen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ProBioGen inks next Commercial GlymaxX® License with Roche

Contact the Supplier

Lead Product(s): GlymaxX

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2020

Details:

ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.